---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-035787"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:17:04.999015+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Madrigal Q4 2024 Rezdiffra sales $103.3M; new 2-year data shows benefit in F4c MASH cirrhosis

## Summary
- Q4 and FY 2024 Rezdiffra net sales $103.3M and $180.1M; no product sales in prior year.
- Over 11,800 patients on Rezdiffra at year-end 2024; cash and marketable securities $931.3M.
- Two-year open-label data in compensated MASH cirrhosis (F4c): mean 6.7 kPa liver stiffness reduction (VCTE), statistically significant vs baseline.
- 51% of F4c patients achieved ≥25% reduction in liver stiffness; safety profile consistent with prior trials.
- MAESTRO-NASH OUTCOMES trial fully enrolled (data anticipated 2027); CHMP opinion expected mid-2025.

## SEC filing metadata
- accession: 0001193125-25-035787
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000119312525035787/0001193125-25-035787-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000119312525035787/d924231d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-035787
- JSON: https://secwatch.observer/filing/0001193125-25-035787.json
- Plain text: https://secwatch.observer/filing/0001193125-25-035787.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.